Skip to content
Peptide research

Imunofan

Also known as Immunomodulatory Hexapeptide
Category
Bioregulators
Administration routes
InjectableNasal
Regulatory status
Not FDA-approved

What it is

A synthetic hexapeptide marketed as an immune modulator for infection recovery and immune balance. Only immune normalization has moderate support; tissue repair, vaccine adjuvant use, epigenetic effects, and anti-tumor support are speculative, mechanism-only, and barely studied in humans. Safety evidence remains limited. Russian labeling lists individual intolerance and possible temporary exacerbation of chronic inflammatory foci. Not FDA-approved, and products sold online are unregulated.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Immunomodulatory activity (immune system normalization)

    Medium

    Multiple human studies, including one randomized trial, show immune parameter improvements.

  • Skin cell proliferation and tissue repair promotion

    Speculative

    Single 2020 study: boosted skin cell growth and wound closure in mice, no human data.

  • Vaccine adjuvant activity

    Speculative

    Single 2025 mouse study suggests adjuvant effect against one bacterial antigen, unreplicated.

Evidence limits

Evidence Level
Moderate Evidence (registered drug with published studies in international journals)

Imunofan has the strongest evidence profile among Khavinson-associated peptides. It has a defined molecular structure enabling rigorous study, a 2020 MDPI publication with detailed in vitro and in vivo data, a 2025 adjuvant study, and decades of Russian clinical use as a registered pharmaceutical. The MDPI study provides Western-accessible peer-reviewed data on mechanism and efficacy. Russian clinical trials have enrolled thousands of patients across multiple indications.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Children under 2 under Russian nasal-spray labeling

    Absolute

    The Russian label permits use in older children; this does not establish FDA approval or comprehensive pediatric safety.

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(3)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Allergic reaction

    Low
  • Potential immune modulation in autoimmune conditions

    Theoretical
  • Injection site reactions (injectable form)

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.